Ditzel, H.J., Itoh, K., and Burton, D.R. (1996). Determinants of polyreactivity m a large panel of recombinant human antibodies from HIV-1 infection. The Journal of Immunology 757, 739-749.
Dock, G. (1904). Influence of complicating diseases upon leukemia. Am. J. Med. Sci. 127, 563-592.
Donin, N., Jurianz, K., Ziporen, L., Schultz, S., Kirschfink, M., and Fishelson, Z. (2003). Complement resistance of human carcinoma cells depends on membranę regulatory proteins, protein kinases and sialic acid. Clinical & Experimental Immunology 131, 254-263.
Doronin, K., Shashkova, E.V., May, S.M., Hofherr, S.E., and Barry, M.A. (2009). Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic Adenovirus. Hum. Gene Ther. 20, 975-988.
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 5, 991-998.
El Hagę, F., Abouzahr-Rifai, S., Meslin, F., Mami-Chouaib, F., and Chouaib, S. (2008). Reponse immune et cancer. Buli. Cancer (Paris) 95, 57-67.
Elvington, M., Huang, Y., Morgan, B.P., Qiao, F., van Rooijen, N., Atkinson, C., and Tomlinson, S. (2012). A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119, 6043-6051.
Emini, E.A., Kao, S.Y., Lewis, A.J., Crainic, R., and Wimmer, E. (1983). Functional basis of polioviius neutralization determined with monospecific neutralizing antibodies J Virol. 46, 466-474.
Eriksson, M., Guse, K., Bauerschmitz, G., Virkkunen, P., Tarkkanen, M., Tanner, M., Hakkarainen, T., Kanerva, A., Desmond, R.A., Pesonen, S., and Hemminki, A. (2007). Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/Low cells. Mol. Ther. 15, 2088-2093.
Eyles, J., Puaux, A.-L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T.G., Zheng, L., Ong, L.C., Jin, Y., et al. (2010). Tumor cells disseminate early, but